Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma-Reference-Cited by-同舟云学术

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

Published:2011-10-11 Issue:1 Volume:107 Page:155-164
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Reardon David A.,Desjardins Annick,Peters Katherine B.,Gururangan Sridharan,Sampson John H.,McLendon Roger E.,Herndon James E.,Bulusu Anuradha,Threatt Stevie,Friedman Allan H.,Vredenburgh James J.,Friedman Henry S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-011-0722-2.pdf

Reference54 articles.

1. Cohen MH, Shen YL, Keegan P, Pazdur R (2009) FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14:1131–1138

2. Wick W, Weller M, van den Bent M, Stupp R (2010) Bevacizumab and recurrent malignant gliomas: a European perspective. J Clin Oncol 28:e188–e189. doi: 10.1200/JCO.2009.26.9027 author reply e190–182

3. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

4. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

5. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 6:227–235

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma;Pharmaceuticals;2024-07-23

2. Safety and Efficiency of Anlotinib in Patients with Recurrent Grade 4 Glioma: A Single-Center Retrospective Analysis;Neurology India;2024-05

3. Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma;BMC Cancer;2024-01-25

4. Unlocking Bevacizumab’s Potential: rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients;Cancers;2023-12-28

5. Rezidiviertes Glioblastom: Daten zur Re-Bestrahlung plus Bevacizumab;InFo Hämatologie + Onkologie;2023-09